Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis.

Pontiroli AE, Tagliabue E.

Acta Diabetol. 2020 Feb 6. doi: 10.1007/s00592-020-01483-y. [Epub ahead of print]

PMID:
32025860
2.

The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy.

Sommariva M, Le Noci V, Bianchi F, Camelliti S, Balsari A, Tagliabue E, Sfondrini L.

Cell Mol Life Sci. 2020 Jan 23. doi: 10.1007/s00018-020-03452-8. [Epub ahead of print] Review.

PMID:
31974656
3.

Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity.

Garavelli S, Bruzzaniti S, Tagliabue E, Prattichizzo F, Di Silvestre D, Perna F, La Sala L, Ceriello A, Mozzillo E, Fattorusso V, Mauri P, Puca AA, Franzese A, Matarese G, Galgani M, de Candia P.

Int J Mol Sci. 2020 Jan 11;21(2). pii: E477. doi: 10.3390/ijms21020477.

4.

Non-Human Determinants of Lung Cancer Outcome: A Target for Inhibition of Pro-Metastatic Effect of Surgery, Triggered by Postoperative Bacterial Pneumonia.

Pastorino U, Tagliabue E.

J Thorac Oncol. 2019 Dec;14(12):2039-2041. doi: 10.1016/j.jtho.2019.09.084. No abstract available.

PMID:
31757372
5.

Bariatric surgery, compared to medical treatment, reduces morbidity at all ages but does not reduce mortality in patients aged < 43 years, especially if diabetes mellitus is present: a post hoc analysis of two retrospective cohort studies.

Pontiroli AE, Ceriani V, Tagliabue E, Zakaria AS, Veronelli A, Folli F, Zanoni I.

Acta Diabetol. 2019 Oct 9. doi: 10.1007/s00592-019-01433-3. [Epub ahead of print]

PMID:
31598798
6.

Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients.

Bianchi F, Milione M, Casalini P, Centonze G, Le Noci VM, Storti C, Alexiadis S, Truini M, Sozzi G, Pastorino U, Balsari A, Tagliabue E, Sfondrini L.

Sci Rep. 2019 Oct 3;9(1):14288. doi: 10.1038/s41598-019-50756-2.

7.

Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.

Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, Vernieri C, de Braud F, Di Nicola M, Tagliabue E, Castagnoli L, Pupa SM.

Cell Oncol (Dordr). 2019 Dec;42(6):815-828. doi: 10.1007/s13402-019-00464-w. Epub 2019 Aug 2.

PMID:
31376137
8.

Percutaneous coronary interventions for stable ischemic heart disease in Italy.

De Servi S, Olivari Z, Crimi G, Marino M, Alberti LP, Tagliabue E, Leonardi S.

J Cardiovasc Med (Hagerstown). 2019 Nov;20(11):762-767. doi: 10.2459/JCM.0000000000000835.

PMID:
31361651
9.

Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia.

Pontiroli AE, Tagliabue E.

Int J Mol Sci. 2019 Jul 25;20(15). pii: E3646. doi: 10.3390/ijms20153646. Review.

10.

Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases.

Le Noci V, Sommariva M, Bianchi F, Triulzi T, Tagliabue E, Balsari A, Sfondrini L.

J Immunol Res. 2019 Jun 20;2019:2015892. doi: 10.1155/2019/2015892. eCollection 2019.

11.

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.

Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Tagliabue E.

Eur J Cancer. 2019 Sep;118:1-9. doi: 10.1016/j.ejca.2019.06.001. Epub 2019 Jul 5.

12.

Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation.

Romero-Cordoba S, Meneghini E, Sant M, Iorio MV, Sfondrini L, Paolini B, Agresti R, Tagliabue E, Bianchi F.

Cancers (Basel). 2019 Jun 28;11(7). pii: E911. doi: 10.3390/cancers11070911.

13.

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?

Castagnoli L, Ladomery M, Tagliabue E, Pupa SM.

Cancers (Basel). 2019 Jun 28;11(7). pii: E902. doi: 10.3390/cancers11070902. Review.

14.

Correction to: Position-based modeling of lesion displacement in ultrasound-guided breast biopsy.

Tagliabue E, Dall'Alba D, Magnabosco E, Tenga C, Peterlik I, Fiorini P.

Int J Comput Assist Radiol Surg. 2019 Nov;14(11):2043. doi: 10.1007/s11548-019-02018-9.

PMID:
31250254
15.

Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients.

Sacchi M, Serafino M, Villani E, Tagliabue E, Luccarelli S, Bonsignore F, Nucci P.

Acta Ophthalmol. 2019 Dec;97(8):e1136-e1140. doi: 10.1111/aos.14166. Epub 2019 Jun 13.

16.

Position-based modeling of lesion displacement in ultrasound-guided breast biopsy.

Tagliabue E, Dall'Alba D, Magnabosco E, Tenga C, Peterlik I, Fiorini P.

Int J Comput Assist Radiol Surg. 2019 Aug;14(8):1329-1339. doi: 10.1007/s11548-019-01997-z. Epub 2019 Jun 3. Erratum in: Int J Comput Assist Radiol Surg. 2019 Jun 27;:.

PMID:
31161556
17.

Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.

Alessi S, Pricolo P, Summers P, Femia M, Tagliabue E, Renne G, Bianchi R, Musi G, De Cobelli O, Jereczek-Fossa BA, Bellomi M, Petralia G.

Eur Radiol. 2019 Oct;29(10):5478-5487. doi: 10.1007/s00330-019-06092-0. Epub 2019 Mar 18.

18.

The landscape of d16HER2 splice variant expression across HER2-positive cancers.

Volpi CC, Pietrantonio F, Gloghini A, Fucà G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, de Braud F, Di Nicola M, Tagliabue E, Pupa SM, Castagnoli L.

Sci Rep. 2019 Mar 5;9(1):3545. doi: 10.1038/s41598-019-40310-5.

19.

Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naïve T2D.

La Sala L, Mrakic-Sposta S, Tagliabue E, Prattichizzo F, Micheloni S, Sangalli E, Specchia C, Uccellatore AC, Lupini S, Spinetti G, de Candia P, Ceriello A.

Cardiovasc Diabetol. 2019 Feb 25;18(1):18. doi: 10.1186/s12933-019-0824-2.

20.

Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors.

Agresti R, Triulzi T, Sasso M, Ghirelli C, Aiello P, Rybinska I, Campiglio M, Sfondrini L, Tagliabue E, Bianchi F.

Cells. 2019 Feb 19;8(2). pii: E181. doi: 10.3390/cells8020181.

21.

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.

Castagnoli L, Cancila V, Cordoba-Romero SL, Faraci S, Talarico G, Belmonte B, Iorio MV, Milani M, Volpari T, Chiodoni C, Hidalgo-Miranda A, Tagliabue E, Tripodo C, Sangaletti S, Di Nicola M, Pupa SM.

Oncogene. 2019 May;38(21):4047-4060. doi: 10.1038/s41388-019-0700-2. Epub 2019 Jan 31.

22.

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors.

Giussani M, Triulzi T, Sozzi G, Tagliabue E.

Cells. 2019 Jan 23;8(2). pii: E81. doi: 10.3390/cells8020081. Review.

23.

Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death.

Beltrán-Anaya FO, Romero-Córdoba S, Rebollar-Vega R, Arrieta O, Bautista-Piña V, Dominguez-Reyes C, Villegas-Carlos F, Tenorio-Torres A, Alfaro-Riuz L, Jiménez-Morales S, Cedro-Tanda A, Ríos-Romero M, Reyes-Grajeda JP, Tagliabue E, Iorio MV, Hidalgo-Miranda A.

Mol Oncol. 2019 Apr;13(4):909-927. doi: 10.1002/1878-0261.12446. Epub 2019 Feb 9.

24.

A 23-year study of mortality and development of co-morbidities in patients with obesity undergoing bariatric surgery (laparoscopic gastric banding) in comparison with medical treatment of obesity.

Pontiroli AE, Zakaria AS, Fanchini M, Osio C, Tagliabue E, Micheletto G, Saibene A, Folli F.

Cardiovasc Diabetol. 2018 Dec 29;17(1):161. doi: 10.1186/s12933-018-0801-1.

25.

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy.

Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, Sfondrini L, Balsari A, Tagliabue E.

Oncoimmunology. 2018 Sep 21;8(1):e1512942. doi: 10.1080/2162402X.2018.1512942. eCollection 2019.

26.

Nomogram-based prediction of cervical dysplasia persistence/recurrence.

Bogani G, Tagliabue E, Ferla S, Martinelli F, Ditto A, Chiappa V, Leone Roberti Maggiore U, Taverna F, Lombardo C, Lorusso D, Raspagliesi F.

Eur J Cancer Prev. 2019 Sep;28(5):435-440. doi: 10.1097/CEJ.0000000000000475.

PMID:
30489353
27.

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.

Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E.

Br J Cancer. 2018 Dec;119(12):1487-1494. doi: 10.1038/s41416-018-0318-0. Epub 2018 Nov 27.

28.

Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients.

Ferro M, Musi G, Serino A, Cozzi G, Mistretta FA, Costa B, Bianchi R, Cordima G, Luzzago S, Di Trapani E, Tagliabue E, Vartolomei MD, Terracciano D, Cassatella MC, Salvatici M, Conti A, Sandri MT, Cioffi A, Turetti M, Catellani M, Bottero D, Matei DV, Mirone V, de Cobelli O.

Urol Int. 2019;102(1):43-50. doi: 10.1159/000494259. Epub 2018 Nov 8.

PMID:
30408799
29.

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M.

Cytokine Growth Factor Rev. 2018 Dec;44:1-10. doi: 10.1016/j.cytogfr.2018.10.005. Epub 2018 Oct 30.

PMID:
30393044
30.

Prognostic value of global left atrial peak strain in patients with acute ischemic stroke and no evidence of atrial fibrillation.

Sonaglioni A, Vincenti A, Baravelli M, Rigamonti E, Tagliabue E, Bassi P, Nicolosi GL, Anzà C, Lombardo M.

Int J Cardiovasc Imaging. 2019 Apr;35(4):603-613. doi: 10.1007/s10554-018-1485-z. Epub 2018 Oct 30.

PMID:
30377893
31.

ECM Remodeling in Breast Cancer with Different Grade: Contribution of 2D-DIGE Proteomics.

Moriggi M, Giussani M, Torretta E, Capitanio D, Sandri M, Leone R, De Palma S, Vasso M, Vozzi G, Tagliabue E, Gelfi C.

Proteomics. 2018 Dec;18(24):e1800278. doi: 10.1002/pmic.201800278.

32.

Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases.

Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, Tagliabue E, Sfondrini L.

Cell Rep. 2018 Sep 25;24(13):3528-3538. doi: 10.1016/j.celrep.2018.08.090.

33.

Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer.

Andriani F, Landoni E, Mensah M, Facchinetti F, Miceli R, Tagliabue E, Giussani M, Callari M, De Cecco L, Colombo MP, Roz L, Pastorino U, Sozzi G.

BMC Cancer. 2018 Sep 18;18(1):899. doi: 10.1186/s12885-018-4772-0.

34.

Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.

Castagnoli L, Iorio E, Dugo M, Koschorke A, Faraci S, Canese R, Casalini P, Nanni P, Vernieri C, Di Nicola M, Morelli D, Tagliabue E, Pupa SM.

J Cell Physiol. 2019 Feb;234(2):1768-1779. doi: 10.1002/jcp.27049. Epub 2018 Aug 21.

35.

Quantification of Circulating Cancer Biomarkers via Sensitive Topographic Measurements on Single Binder Nanoarrays.

Ambrosetti E, Paoletti P, Bosco A, Parisse P, Scaini D, Tagliabue E, de Marco A, Casalis L.

ACS Omega. 2017 Jun 30;2(6):2618-2629. doi: 10.1021/acsomega.7b00284. Epub 2017 Jun 13.

36.

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab.

Cataldo A, Piovan C, Plantamura I, D'Ippolito E, Camelliti S, Casalini P, Giussani M, Déas O, Cairo S, Judde JG, Tagliabue E, Iorio MV.

Oncotarget. 2018 Jun 15;9(46):27920-27928. doi: 10.18632/oncotarget.24723. eCollection 2018 Jun 15.

37.

Gender differences in chronic obstructive pulmonary diseases: a narrative review.

Nicolini A, Barbagelata E, Tagliabue E, Colombo D, Monacelli F, Braido F.

Panminerva Med. 2018 Dec;60(4):192-199. doi: 10.23736/S0031-0808.18.03463-8. Epub 2018 Jun 1. Review.

PMID:
29856178
38.

MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project.

Tagliabue E, Gandini S, Bellocco R, Maisonneuve P, Newton-Bishop J, Polsky D, Lazovich D, Kanetsky PA, Ghiorzo P, Gruis NA, Landi MT, Menin C, Fargnoli MC, García-Borrón JC, Han J, Little J, Sera F, Raimondi S.

Cancer Manag Res. 2018 May 14;10:1143-1154. doi: 10.2147/CMAR.S155283. eCollection 2018.

39.

The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.

Forte L, Turdo F, Ghirelli C, Aiello P, Casalini P, Iorio MV, D'Ippolito E, Gasparini P, Agresti R, Belmonte B, Sozzi G, Sfondrini L, Tagliabue E, Campiglio M, Bianchi F.

BMC Cancer. 2018 May 23;18(1):586. doi: 10.1186/s12885-018-4500-9.

40.

cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells.

Majorini MT, Manenti G, Mano M, De Cecco L, Conti A, Pinciroli P, Fontanella E, Tagliabue E, Chiodoni C, Colombo MP, Delia D, Lecis D.

Cell Death Differ. 2018 Dec;25(12):2147-2164. doi: 10.1038/s41418-018-0100-0. Epub 2018 Apr 19.

41.

Nutritional intervention in head and neck cancer patients during chemo-radiotherapy.

Della Valle S, Colatruglio S, La Vela V, Tagliabue E, Mariani L, Gavazzi C.

Nutrition. 2018 Jul - Aug;51-52:95-97. doi: 10.1016/j.nut.2017.12.012. Epub 2018 Feb 5.

PMID:
29625408
42.

MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer.

Dugo M, Huang X, Iorio MV, Cataldo A, Tagliabue E, Daidone MG, Wu J, Orlandi R.

Breast. 2018 Jun;39:46-52. doi: 10.1016/j.breast.2018.03.008. Epub 2018 Mar 26.

PMID:
29597130
43.

A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses.

Bogani G, Tagliabue E, Signorelli M, Ditto A, Martinelli F, Chiappa V, Mosca L, Sabatucci I, Leone Roberti Maggiore U, Lorusso D, Raspagliesi F.

J Gynecol Oncol. 2018 May;29(3):e40. doi: 10.3802/jgo.2018.29.e40. Epub 2018 Feb 23.

44.

Extracellular matrix proteins as diagnostic markers of breast carcinoma.

Giussani M, Landoni E, Merlino G, Turdo F, Veneroni S, Paolini B, Cappelletti V, Miceli R, Orlandi R, Triulzi T, Tagliabue E.

J Cell Physiol. 2018 Aug;233(8):6280-6290. doi: 10.1002/jcp.26513. Epub 2018 Mar 9.

PMID:
29521413
45.

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.

Di Modica M, Tagliabue E, Triulzi T.

Dis Markers. 2017;2017:7849108. doi: 10.1155/2017/7849108. Epub 2017 Dec 18. Review.

46.

Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter?

Sanguedolce F, Petralia G, Sokhi H, Tagliabue E, Anyamene N, Hellawell G, Padhani AR.

Clin Genitourin Cancer. 2018 Apr;16(2):155-163.e6. doi: 10.1016/j.clgc.2017.10.020. Epub 2017 Nov 21.

PMID:
29198639
47.

Occurrence of ultrasound-detected symptomatic and asymptomatic central vein catheter-related thrombosis in pediatric oncology patients.

Gandini L, Previtali P, Paladini S, Allemano MC, Morosi C, Tagliabue E, Codazzi D, Massimino M.

Ann Oncol. 2017 Oct;28 Suppl 6:vi80. doi: 10.1093/annonc/mdx433.004. No abstract available.

48.

Prospective translational study investigating circulating predictors of outcome to first-line pazopanib in patients with metastatic renal cell carcinoma (mRCC).

Grassi P, Verzoni E, Ratta R, Martinetti A, Montone R, Tagliabue E, de Braud F, Procopio G.

Ann Oncol. 2017 Oct;28 Suppl 6:vi18. doi: 10.1093/annonc/mdx423.005. No abstract available.

49.

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C, Tagliabue E, Iezzi M, Nanni P, Lollini PL.

Oncotarget. 2017 Apr 13;8(33):54444-54458. doi: 10.18632/oncotarget.17088. eCollection 2017 Aug 15.

50.

Exploiting poly(I:C) to induce cancer cell apoptosis.

Bianchi F, Pretto S, Tagliabue E, Balsari A, Sfondrini L.

Cancer Biol Ther. 2017 Oct 3;18(10):747-756. doi: 10.1080/15384047.2017.1373220. Epub 2017 Sep 7. Review.

Supplemental Content

Loading ...
Support Center